Wendell Wierenga, Ph.D., age 65, has been a member of our board of directors since 2000. He is executive vice president, research and development at Santarus, Inc., a pharmaceutical company. Prior to joining Santarus in June 2011, he was executive vice president of research and development at Ambit Biosciences, Inc., a biopharmaceutical company engaged in the discovery and development of small-molecule kinase inhibitors, since January 2007. Dr. Wierenga served as executive vice president of research and development at Neurocrine Biosciences, Inc., a biopharmaceutical company developing therapeutics for neuropsychiatric, neuroinflammatory and neurodegenerative diseases, from 2003 to 2007. From 2000 to 2003, Dr. Wierenga was chief executive officer of Syrrx, Inc., a company focused on small-molecule drug compounds. Prior to joining Syrrx, from 1990 to 2000, he was senior vice president of worldwide pharmaceutical sciences, technologies and development at Parke-Davis, a division of Warner Lambert Co., a pharmaceutical company. Pfizer Inc., a research-based pharmaceutical company, acquired Warner Lambert in 2000. Prior to Parke-Davis, Dr. Wierenga worked at Upjohn Co., later Pharmacia & Upjohn, Inc., a pharmaceutical and biotechnology company, for 16 years in various positions, most recently as executive director of discovery research. Pfizer acquired Pharmacia & Upjohn, then named Pharmacia Corp., in 2002. Dr. Wierenga received a B.S. from Hope College and a Ph.D. in chemistry from Stanford University. Dr. Wierenga is a member of the boards of directors of Onyx Pharmaceuticals, Inc. and Cytokinetics, Inc., which are publicly-traded biopharmaceutical companies.
Who said anything about awards impacting DIS earnings or the success of Frozen and its contribution to the bottom line? Any time you can create animated content in film that is THIS financially successful and it can move through the lifecycle machine that is Disney, Frozen will be positively impacting DIS earnings for years and years and years to come.
So it is not too late to get in - join us - - the water is just fine!
I believe NFLX is a REAL possibility - would certainly explain why Disney has been busy getting all cozy with Netflix; they are in the know.
Hold - with the Parks numbers being up for DIS, I would say that the jobs number may be better than expected. With a terrific jobs number tomorrow DIS could be up another 2 bucks.
Ladies and gentlemen, single file please. Do not crowd the exits. Please proceed in an orderly fashion. Noone yell 'Fire' in the theatre.
... My goodness DIS is going to trade a lot of shares today and will close decidedly higher.
That is what is so great about the long term prospects of INCY - - you don't know which Big Pharma will end up with her. Like the prettiest girl at the dance and all the guys are dancing with her but who will she leave the dance with???
Wells has more of their investment customers who want on board at a lower price.
Those wanting to buy in had better hurry...
BCRX is putting up the good fight today.
I believe once the Wells Fargo clients secure their shares on the cheap it will be up we go.
While I think this sort of activity is shameful (by Wells and others who do this) the art of diversification is if you cannot beat them join them so I am a Wells Fargo shareholder as well!
Good Fortune all!
Are the most important of Tim Cook's career and I argue one of the most important inflection points for the company. My prediction? RECORD SETTING to the upside. All the stars are aligning for Apple's explosive surge upward. Good Fortunes folks!
Agreed. My average in is around $5. I think this will return to $100+ share price - hopefully before it gets bought out. What with the meteoric rise this week of Incept I think a lot of big pharmas will begin to panic and look to acquire prior to others having a meteoric rise.